Despite Disappointment - Alzheimer’s Drug Development and Testing Continues
If you or a family member has been affected by Alzheimer’s disease, then you probably pay close attention to news about the latest drug research and other efforts to combat or even reverse the dreadful affliction.
There have been many experimental drugs tested and some have even reached the market. Drugs such as Aricept and Namenda have been shown to temporarily deal with symptoms of the disease but done nothing to stop its advancement. Now the latest results of trials of the drug known as LMTX have shown it is no more effective.
A New York Times article titled “Alzheimer’s Drug LMTX Falters in Final Stage of Trials” highlighted the unwelcomed trial results. “Over all, the patients who received LMTX, which was developed by TauRx Therapeutics, did not have a slower rate of decline in mental ability or daily functioning than those in the control group” according to the Times.
This new type of drug for Alzheimer’s disease failed to slow the rate of decline in mental ability and daily functioning in its first large clinical trial, though prior to the latest study there was hopefulness. It seemed a small portion of the study participants saw favorable results. “There were highly significant, clinically meaningful, large effects in patients taking the drug as monotherapy, and no effect in patients taking it as an add-on,” Claude Wischik, a founder and the chief executive of TauRx, said in an interview. He spoke from Toronto, where the results were being presented at the Alzheimer’s Association International Conference. Monotherapy has the meaning that only the test drug was being administered, with no other related drug(s).
Future of the drug LMTX still to be determined in spite of results.
Although some people associated with the TauRx study said there were some hopeful results, other experts not involved in the study were skeptical about drawing conclusions from a small subset of patients, especially since there was no obvious explanation why LMTX would be expected to work only in patients not getting other drugs. Regulators might also be skeptical and require the company to conduct another large study, this time only with participants not using other drugs.
“I have to say that the results that we saw here were, to me, more disappointing than not,” Dr. David Knopman, a neurologist at the Mayo Clinic, said in moderating a news conference at the meeting in Toronto.
Regardless of these mostly disappointing results, Dr. Wischik said the company planned to apply for approval of LMTX to be used by itself.
The Phase 3 trial presented on Wednesday had 891 patients from 16 countries with mild or moderate Alzheimer’s disease. They were randomly assigned to be treated with a lower dose of LMTX, a higher dose of LMTX or a placebo. (The placebo contained a tiny amount of LMTX to turn the patients’ urine bluish green. Otherwise people would know if they were getting the drug or the placebo based on the color of their urine.)
The decision of the company to continue with the drug LMTX certainly shows there is an obvious great desire for work to continue on Alzheimer’s research, with the hope of one day discovering genuinely effective drug treatment for what today seems an unstoppable disease.
Senior Care Homes that cater to Alzheimer’s patients can be found at Senior Home Search
Senior Home Search provides free location information for thousands of Senior Care Homes, Adult Foster Care Homes and other facilities in the U.S. Many of the homes listed on our website have special programs for residents who have Alzheimer’s. You can use the information about these homes to contact them directly and inquire about whether they cater to Alzheimer’s sufferers and what training their staff may have.
Senior Home Search will always give you contact information so you can talk directly with these homes.
Please take advantage of this free and easy to use website to find Assisted Living and Senior Homes near you. And remember to tell your friends about it. Good luck to all in your search.